Alpa Laboratories credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2.52.50.05.22.3
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−135−135−113−87.6−79.9
0.01×0.01×0.00×0.03×0.02×
−0.73×−0.73×−0.66×−0.58×−0.59×
0.76×0.76×0.00×0.65×0.30×
124.08×−41.14×−23.71×−10.81×−10.57×
4.64×4.64×11.01×17.13×27.89×
1.3%1.3%0.0%3.3%1.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALPA₹52.62

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹111 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt2.35.20.02.52.5
Net Debt-79.9-87.6-112.7-135.4-135.4
Total Debt/Equity0.020.030.000.010.01
Net Debt/Equity-0.59-0.58-0.66-0.73-0.73
Total Debt/EBITDA0.300.650.000.760.76
Net Debt/EBITDA-10.57-10.81-23.71-41.14124.08
Interest Coverage (EBIT/Interest)27.8917.1311.014.644.64
Total Debt/Total Capital %1.683.340.001.331.33
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.